Philip Morris International to Host Webcast of 2025 Fourth-Quarter and Full-Year Results

Core Viewpoint - Philip Morris International (PMI) is transitioning towards a smoke-free future by diversifying its product portfolio beyond traditional tobacco and nicotine products, focusing on innovative smoke-free alternatives [1] Product Portfolio - PMI's current offerings include cigarettes and smoke-free products such as heat-not-burn, nicotine pouches, and e-vapor products [1] - As of June 30, 2025, PMI estimates that over 41 million legal-age consumers globally are using its smoke-free products, many of whom have reduced or stopped cigarette consumption [1] - The smoke-free segment contributed to 41% of PMI's total net revenues in the first nine months of 2025 [1] Investment and Development - Since 2008, PMI has invested over $14 billion in the development and commercialization of smoke-free products aimed at adult smokers [1] - The company has established scientific assessment capabilities in areas such as pre-clinical systems toxicology, clinical and behavioral research, and post-market studies [1] Regulatory Approvals - The U.S. Food and Drug Administration (FDA) has authorized the marketing of Swedish Match's General snus and ZYN nicotine pouches, as well as versions of PMI's IQOS devices and consumables, marking the first-ever authorizations in their categories [1] - IQOS devices and General snus have also received the first-ever Modified Risk Tobacco Product authorizations from the FDA [1] Future Ambitions - PMI aims to leverage its expertise in life sciences to expand into wellness and healthcare sectors, focusing on enhancing life through seamless health experiences [1]